Joel Greenblatt Biotechnology

Gotham Asset Management, LLC

$10.2 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
UTHR United Therapeutics Corp	$16.9B	$21.6 Million 0.21% of portfolio	61,179	Q4 2024 Added 17.52%
EXEL Exelixis, Inc.	$11.3B	$14.2 Million 0.14% of portfolio	427,855	Q4 2024 Added 41.92%
VRTX Vertex Pharmaceuticals Inc	$118B	$12.1 Million 0.12% of portfolio	30,111	Q4 2024 Added 10.98%
REGN Regeneron Pharmaceuticals, Inc.	$72.2B	$8.14 Million 0.08% of portfolio	11,423	Q4 2024 Added 103.0%
INCY Incyte Corp	$15.7B	$5.34 Million 0.05% of portfolio	77,313	Q4 2024 Added 18.23%
ADMA Adma Biologics, Inc.	$3.12B	$2.86 Million 0.03% of portfolio	166,694	Q4 2024 Added 1.29%
MRNA Moderna, Inc.	$12.9B	$2.67 Million 0.03% of portfolio	64,220	Q4 2024 New
ALNY Alnylam Pharmaceuticals, Inc.	$31.6B	$2.57 Million 0.03% of portfolio	10,924	Q4 2024 Reduced 37.84%
HALO Halozyme Therapeutics, Inc.	$8.12B	$2.27 Million 0.02% of portfolio	47,440	Q4 2024 Added 9.66%
MRVI Maravai Lifesciences Holdings, Inc.	$552M	$1.89 Million 0.02% of portfolio	347,015	Q4 2024 Reduced 25.83%
JAZZ Jazz Pharmaceuticals PLC	$8.4B	$1.86 Million 0.02% of portfolio	15,091	Q4 2024 Reduced 28.25%
HRMY Harmony Biosciences Holdings, Inc.	$2.31B	$1.74 Million 0.02% of portfolio	50,502	Q4 2024 Reduced 24.31%
TGTX Tg Therapeutics, Inc.	$4.46B	$1.53 Million 0.02% of portfolio	50,949	Q4 2024 Reduced 55.8%
ACAD Acadia Pharmaceuticals Inc	$3.24B	$1.28 Million 0.01% of portfolio	69,966	Q4 2024 Added 95.84%
CORT Corcept Therapeutics Inc	$7.79B	$964,000 0.01% of portfolio	19,137	Q4 2024 Added 2.81%
CPRX Catalyst Pharmaceuticals, Inc.	$2.39B	$812,000 0.01% of portfolio	38,953	Q4 2024 Added 7.78%
ACLX Arcellx, Inc.	$2.79B	$800,000 0.01% of portfolio	10,508	Q4 2024 Reduced 19.18%
VCYT Veracyte, Inc.	$2.94B	$794,000 0.01% of portfolio	20,057	Q4 2024 Added 21.5%
APLS Apellis Pharmaceuticals, Inc.	$3.01B	$775,000 0.01% of portfolio	24,299	Q4 2024 New
BMRN Biomarin Pharmaceutical Inc	$12.1B	$771,000 0.01% of portfolio	11,734	Q4 2024 Reduced 49.84%
INVA Innoviva, Inc.	$1.26B	$761,000 0.01% of portfolio	43,899	Q4 2024 Added 37.24%
VCEL Vericel Corp	$2.69B	$750,000 0.01% of portfolio	13,663	Q4 2024 Added 0.07%
ROIV Roivant Sciences Ltd.	$7.44B	$461,000 0.0% of portfolio	39,027	Q3 2024 Reduced 1.29%
AUPH Aurinia Pharmaceuticals Inc.	$1.11B	$404,000 0.0% of portfolio	44,996	Q4 2024 Added 8.84%
RYTM Rhythm Pharmaceuticals, Inc.	$3.21B	$379,000 0.0% of portfolio	6,786	Q4 2024 Reduced 28.35%
MNKD Mannkind Corp	$1.39B	$341,000 0.0% of portfolio	53,066	Q4 2024 Added 22.42%
GANX Gain Therapeutics, Inc.	$29.6M	$322,000 0.0% of portfolio	158,155	Q4 2024 Reduced 52.73%
BPMC Blueprint Medicines Corp	$5.61B	$309,000 0.0% of portfolio	3,545	Q4 2024 New
SMMT Summit Therapeutics Inc.	$3.96B	$281,000 0.0% of portfolio	15,785	Q4 2024 Reduced 0.77%
IONS Ionis Pharmaceuticals Inc	$4.41B	$218,000 0.0% of portfolio	6,260	Q4 2024 Reduced 0.03%

Shares Options

Joel Greenblatt

Joel Greenblatt is the founder and managing partner of Gotham Asset Management, a successful investment firm that focuses on value investing. Greenblatt is known for his expertise in value investing and his contrarian approach to investing. He has generated strong returns for his clients over the long term.

Track Joel Greenblatt's portfolio

Track Joel Greenblatt's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.

Account